Bushnell, David <br/><br/>
Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.  [electronic resource] 

 -  Cancer biotherapy & radiopharmaceuticals  Feb 2004 
 - 35-41 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1084-9785 
<br/><br/><label>Standard No.: </label>10.1089/108497804773391658  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Amino Acids--administration & dosage<br/>Arginine--administration & dosage<br/>Carcinoid Tumor--metabolism<br/>Female<br/>Humans<br/>Infusions, Intravenous<br/>Kidney--drug effects<br/>Lung Neoplasms--metabolism<br/>Lysine--administration & dosage<br/>Male<br/>Meningioma--metabolism<br/>Middle Aged<br/>Octreotide--administration & dosage<br/>Pancreatic Neoplasms--metabolism<br/>Radiopharmaceuticals--administration & dosage<br/>Yttrium Radioisotopes--administration & dosage